

**Editor**

Josef S Smolen

**Associate Editors**

Francis Berenbaum  
Dimitrios Boumpas  
Gerd Burmester  
Mary Crow  
Iain McInnes  
Thomas Pap  
David Pisetsky  
Désirée van der Heijde  
Kazuhiko Yamamoto

**Editorial office**

Annals of the Rheumatic Diseases  
BMJ Publishing Group Ltd  
BMA House  
Tavistock Square  
London WC1H 9JR, UK  
T: +44 (0)20 3655 5610  
E: [ard@bmj.com](mailto:ard@bmj.com)  
Twitter: @ARD\_BMJ  
ISSN: 0003-4967 (print)  
ISSN: 1468-2060 (online)  
Impact Factor: 12.811

**Disclaimer:** ARD is owned and published by BMJ Publishing Group Ltd (a wholly owned subsidiary of the British Medical Association) and the European League Against Rheumatism. The owners grant editorial freedom to the Editor of ARD. ARD follows guidelines on editorial independence produced by the World Association of Medical Editors and the code on good publication practice of the Committee on Publication Ethics.

ARD is intended for medical professionals and is provided without warranty, express or implied. Statements in the journal are the responsibility of their authors and advertisers and not authors' institutions the BMJ Publishing Group, the European League Against Rheumatism or the BMA unless otherwise specified or determined by law. Acceptance of advertising does not imply endorsement.

To the fullest extent permitted by law, the BMJ Publishing Group shall not be liable for any loss, injury or damage resulting from the use of ARD or any information in it whether based on contract, tort, or otherwise. Readers are advised to verify any information they choose to rely on.

**Copyright:** © 2018 BMJ Publishing Group and European League Against Rheumatism. All rights reserved; no part of this publication may be reproduced stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying recording, or otherwise without prior permission

ARD is published by BMJ Publishing Group Ltd typeset by Exeter Premedia Services Private Ltd, Chennai, India and printed in the UK on acid-free paper.

*Annals of the Rheumatic Diseases* (ISSN No: 0003-4967) is published monthly by BMJ Publishing Group and distributed in the USA by Air Business Ltd. Periodicals postage paid at Jamaica NY 11431  
POSTMASTER: send address changes to *Annals of the Rheumatic Diseases*, Air Business Ltd, c/o Worldnet Shipping Inc., 156-15, 146th Avenue, 2nd Floor, Jamaica, NY 11434, USA.

**Editorial**

- 961** Adalimumab for childhood onset uveitis  
*A V Ramanan, C Guly*

**Thinking the unthinkable**

- 963** Rheumatology 4.0: big data, wearables and diagnosis by computer  
*G R Burmester*

**Viewpoint**

- 966** Defining refractory rheumatoid arthritis  
*M H Buch*

**Clinical and epidemiological research**

- 970** Exposure to passive smoking and rheumatoid arthritis risk: results from the Swedish EIRA study  
*A K Hedström, L Klareskog, L Alfredsson*

- 973** Biomechanical properties of bone are impaired in patients with ACPA-positive rheumatoid arthritis and associated with the occurrence of fractures  
*F Stemmler, D Simon, A-M Liphardt, M Englbrecht, J Rech, A J Hueber, K Engelke, G Schett, A Kleyer*

- 981** High erythrocyte levels of the n-6 polyunsaturated fatty acid linoleic acid are associated with lower risk of subsequent rheumatoid arthritis in a southern European nested case-control study  
*P de Pablo, D Romaguera, H L Fiske, P C Calder, A-M Quirke, A J Cartwright, S Panico, A Mattiello, D Gavrilu, C Navarro, C Sacerdote, P Vineis, R Tumino, W E Ollier, D S Michaud, E Riboli, P J Venables, B A Fisher*

- 988** Lipid profile and effect of statin treatment in pooled phase II and phase III baricitinib studies  
*P C Taylor, J M Kremer, P Emery, S H Zuckerman, G Ruotolo, J Zhong, L Chen, S Witt, C Saifan, M Kurzawa, J D Otvos, M A Connelly, W L Macias, D E Schlichting, T P Rooney, S de Bono, I B McInnes*

- 996** Time spent in inactive disease before MTX withdrawal is relevant with regard to the flare risk in patients with JIA  
*J Klotsche, K Minden, M Niewerth, G Horneff*

- 1003** ADJUVITE: a double-blind, randomised, placebo-controlled trial of adalimumab in early onset, chronic, juvenile idiopathic arthritis-associated anterior uveitis  
*P Quartier, A Baptiste, V Despert, E Allain-Launay, I Koné-Paut, A Belot, L Kodjikian, D Monnet, M Weber, C Elie, B Bodaghi, On behalf of the ADJUVITE Study Group*

- 1012** Risk of malignancy associated with paediatric use of tumour necrosis factor inhibitors  
*T Beukelman, F Xie, L Chen, D B Horton, J D Lewis, R Mamtani, M M Mannion, K G Saag, J R Curtis*

- 1017** Determinants of psychological well-being in axial spondyloarthritis: an analysis based on linked claims and patient-reported survey data  
*I Redeker, F Hoffmann, J Callhoff, H Haibel, J Sieper, A Zink, D Poddubnyy*

- 1025** Sialendoscopy enhances salivary gland function in Sjögren's syndrome: a 6-month follow-up, randomised and controlled, single blind study  
*K H Karagozoglou, A Vissink, T Forouzanfar, H S Brand, F Maarse, D H J Jager*

- 1032** Common measure of quality of life for people with systemic sclerosis across seven European countries: a cross-sectional study  
*M Ndosi, B Alacacer-Pitarch, Y Allanore, F del Galdo, M Frerix, S Garcia-Diaz, R Hesselstrand, C Kendall, M Matucci-Cerinic, U Mueller-Ladner, G Sandqvist, V Torrente-Segarra, T Schmeiser, M Sierakowska, J Sierakowska, S Sierakowski, A Redmond*

- 1039** MR-PheWAS: exploring the causal effect of SUA level on multiple disease outcomes by using genetic instruments in UK Biobank  
*X Li, X Meng, A Spiliopoulou, M Timofeeva, W-Q Wei, A Gifford, X Shen, Y He, T Varley, P McKeigue, I Tzoulaki, A F Wright, P Joshi, J C Denny, H Campbell, E Theodoratou*

- 1048** Relationship between serum urate concentration and clinically evident incident gout: an individual participant data analysis  
*N Dalbeth, A Phipps-Green, C Frampton, T Neogi, W J Taylor, T R Merriman*

MORE CONTENTS ►



This article has been chosen by the Editor to be of special interest or importance and is freely available online.

This article has been made freely available online under the BMJ Journals Open Access scheme.

See <http://authors.bmj.com/open-access/>



Member since 2008  
JMS0004

This journal is a member of and subscribes to the principles of the Committee on Publication Ethics

<http://publicationethics.org/>



When you have finished with this please recycle it

## Basic and translational research

- 1053** Hypermetabolic macrophages in rheumatoid arthritis and coronary artery disease due to glycogen synthase kinase 3b inactivation  
*M Zeisbrich, R E Yanes, H Zhang, R Watanabe, Y Li, L Brosig, J Hong, B B Wallis, J C Giacomini, T L Assimes, J J Goronzy, C M Weyand*
- 1063** Novel gene variants associated with cardiovascular disease in systemic lupus erythematosus and rheumatoid arthritis  
*D Leonard, E Svenungsson, J Dahlqvist, A Alexsson, L Ärlestig, K E Taylor, J K Sandling, C Bengtsson, M Frodlund, A Jönsen, S Ekeijäll, K Jensen-Urstad, I Gunnarsson, C Sjöwall, A A Bengtsson, M-L Eloranta, A-C Syvänen, S Rantapää-Dahlqvist, L A Criswell, L Rönnblom*
- 1070** The *STAT4* SLE risk allele rs7574865[T] is associated with increased IL-12-induced IFN- $\gamma$  production in T cells from patients with SLE  
*N Hagberg, M Joelsson, D Leonard, S Reid, M-L Eloranta, J Mo, M K Nilsson, A-C Syvänen, Y T Bryceson, L Rönnblom*
- 1078** Identification of *ST3AGL4*, *MFHAS1*, *CSNK2A2* and *CD226* as loci associated with systemic lupus erythematosus (SLE) and evaluation of SLE genetics in drug repositioning  
*Y-F Wang, Y Zhang, Z Zhu, T-Y Wang, D L Morris, J J Shen, H Zhang, H-F Pan, J Yang, S Yang, D-Q Ye, T J Vyse, Y Cui, X Zhang, Y Sheng, Y L Lau, W Yang*

## Letters

- 1085** A disconnect between disease activity and functional ability already in patients with early rheumatoid arthritis, depending on large joint involvement  
*A Rubbert-Roth, J W G Jacobs, J W J Bijlsma, P M J Welsing*
- 1087** The extensive glycosylation of the ACPA variable domain observed for ACPA-IgG is absent from ACPA-IgM  
*A C Kempers, L Hafkenscheid, A L Dorjée, E Moutousidou, F S van de Bovenkamp, T Rispens, L A Trouw, M van Oosterhout, T W J Huizinga, R Toes, H U Scherer*
- 1088** Inflammatory features of infrapatellar fat pad in rheumatoid arthritis versus osteoarthritis reveal mostly qualitative differences  
*A J de Jong, I R Klein-Wieringa, J C Kwekkeboom, R E M Toes, M Kloppenburg, A Ioan-Facsinay*
- 1091** Evaluation of the effect of baseline MRI sacroiliitis and C reactive protein status on etanercept treatment response in non-radiographic axial spondyloarthritis: a post hoc analysis of the EMBARK study  
*M A Brown, P A Bird, P C Robinson, P J Mease, F van den Bosch, C Surian, H Jones, A Szumski, L Marshall, Z Wüid, M Dougados*

- 1093** Serum neurofilament light chain: a biomarker of neuronal injury in vasculitic neuropathy  
*A Bischof, T Manigold, C Barro, I Heijnen, C T Berger, T Derfuss, J Kuhle, T Daikeler*

## Electronic pages

- e35** Concerns on glucocorticoid use for Japanese patients with established rheumatoid arthritis  
*H Oiwa*
- e36** Response to: 'Concerns on glucocorticoid use for Japanese patients with established rheumatoid arthritis' by Oiwa  
*J S Smolen*
- e37** What is the agreement between pathological features of parotid gland and labial salivary gland biopsies?  
*G C Alegria, S Costa, S Jousse-Joulin, P Marcorettes, J-O Pers, A Saraux, V Devauchelle-Pensec, D Cornec*
- e38** The parotid gland connection: ultrasound and biopsies in primary Sjögren's syndrome  
*E Mossel, K Delli, J F van Nimwegen, A J Stel, E A Haacke, F G M Kroese, F K L Spijkervet, A Vissink, S Arends, H Bootsma*
- e39** Different glucosamine sulfate products generate different outcomes on osteoarthritis symptoms  
*J-Y L Reginster, O Bruyere, C Cooper*
- e40** Response to: 'Different glucosamine sulfate products generate different outcomes on osteoarthritis symptoms' by Reginster *et al*  
*J Runhaar, R M Rozendaal, M van Middlekoop, H J W Bijlsma, M Doherty, K S Dziedzic, L S Lohmander, T McAlindon, W Zhang, S B Zeinstra*
- e41** Lesinurad combination therapy with allopurinol in gout: do CLEAR studies make the treatment of gout clearer?  
*R Valiyil, B Schechter*
- e42** Response to: 'A response to Singh. "Lesinurad combination therapy with allopurinol in gout: do CLEAR studies make the treatment of gout clearer?"' by Valiyil and Schechter  
*J A Singh*
- e43** Correction
- e44** Correction
- e45** Correction
- e46** Retracted: Methotrexate in the treatment of symptomatic knee osteoarthritis: randomised placebo-controlled trial  
*A Abou-Raya, S Abou-Raya, T Khadrawe*